Relay Therapeutics, Inc. (RLAY) Misses Q2 EPS by 1c, misses on revenue

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.81), $0.01 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $719.44 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c